Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GlaxoSmithKline, Gilead HIV Combos Clear FDA

Executive Summary

GlaxoSmithKline will use a 60-day supply voucher program to help establish a patient base for its HIV-1 lamivudine/abacavir fixed-dose combination treatment Epzicom

You may also be interested in...

FDA Guidance On Combo HIV Products Will Allow Reviews In Six Weeks

FDA is setting a goal of reviewing fixed-dose combinations of HIV drugs in six weeks as part of the Bush Administration's $15 bil. Emergency Plan for AIDS Relief

Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life

Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts